Latest Period
Q1 2026
Security Snapshot
ACADIA PHARMACEUTICALS INC - Common Stock (ACAD) Institutional Ownership
CUSIP: 004225108
13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026
Institutions Reporting
339
Shares (Excl. Options)
164,739,362
Price
$22.26
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- ACAD on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 164,739,362
- Total 13F value
- $3,666,700,528
- Portfolio coverage rank
- 0%
- Share change
- -1,912,374
- Value change
- -$63,003,861
- Number of holders
- 339
- Shares outstanding
- 170,504,990
- SEC-reported price per share
- $22.67
- Insider filing price
- $22.67
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ACAD - ACADIA PHARMACEUTICALS INC - Common Stock is tracked under CUSIP 004225108.
- 339 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 333 to 339 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $4,442,292,109 to $3,666,700,528.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 339 institutions filings for Q1 2026.
Security key
004225108
Latest holder period
Q1 2026
13F holders
339
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
ACAD full holder history
ACADIA PHARMACEUTICALS INC SEC filings
ACADIA PHARMACEUTICALS INC company facts
ACADIA PHARMACEUTICALS INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 004225108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
ACAD
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 25% | $1,162,886,859 | 43,294,373 | Julian C. Baker | 24 Feb 2026 | |||
| BlackRock, Inc. | 12% | $292,813,929 | 19,878,746 | BlackRock, Inc. | 31 Jan 2025 | |||
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.2% | $195,465,216 | 8,781,007 | Vanguard Portfolio Management | 31 Mar 2026 | |||
| RTW INVESTMENTS, LP | 4.2% | -20% | $152,464,142 | -$33,311,249 | 7,144,524 | -18% | RTW Investments, LP | 30 Sep 2025 |
As of 31 Mar 2026, 339 institutional investors reported holding 164,739,362 shares of ACADIA PHARMACEUTICALS INC - Common Stock (ACAD). This represents 97% of the company’s total 170,504,990 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
76%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 25% | 42,896,690 | 0% | 5.5% | $954,880,319 |
| BlackRock, Inc. | 13% | 21,550,921 | +3.8% | 0.01% | $479,723,502 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.1% | 8,671,645 | 0% | 0.01% | $193,030,818 |
| STATE STREET CORP | 4.9% | 8,332,771 | +5.3% | 0.01% | $185,487,482 |
| RTW INVESTMENTS, LP | 4.2% | 7,144,524 | 0% | 1.6% | $159,037,104 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.3% | 5,661,400 | 0% | 0% | $126,022,764 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 3,464,689 | +7% | 0% | $77,137,406 |
| FIRST TRUST ADVISORS LP | 2% | 3,343,868 | +47% | 0.05% | $74,434,501 |
| DIMENSIONAL FUND ADVISORS LP | 1.9% | 3,155,160 | +8% | 0.01% | $70,221,842 |
| Palo Alto Investors LP | 1.7% | 2,872,695 | +16% | 9.8% | $63,946,191 |
| Point72 Asset Management, L.P. | 1.5% | 2,577,916 | -24% | 0.1% | $57,384,410 |
| BRAIDWELL LP | 1.4% | 2,471,199 | +22% | 1.8% | $55,008,890 |
| Pictet Asset Management Holding SA | 1.2% | 2,026,044 | +31% | 0.05% | $44,736,128 |
| RENAISSANCE TECHNOLOGIES LLC | 1% | 1,724,196 | +13% | 0.06% | $38,380,603 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 0.92% | 1,569,491 | +4.5% | 0.02% | $34,936,870 |
| GOLDMAN SACHS GROUP INC | 0.91% | 1,557,804 | -0.78% | 0% | $34,676,717 |
| BANK OF AMERICA CORP /DE/ | 0.91% | 1,553,770 | +27% | 0% | $34,586,921 |
| Frazier Life Sciences Management, L.P. | 0.84% | 1,438,198 | +11% | 0.82% | $32,014,287 |
| Artisan Partners Limited Partnership | 0.78% | 1,331,813 | 0.05% | $29,646,157 | |
| FRED ALGER MANAGEMENT, LLC | 0.75% | 1,277,151 | -18% | 0.12% | $28,429,382 |
| NORTHERN TRUST CORP | 0.75% | 1,272,611 | +3% | 0% | $28,328,322 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.69% | 1,173,560 | +0.11% | 0% | $26,123,446 |
| MORGAN STANLEY | 0.64% | 1,093,151 | -4.3% | 0% | $24,333,551 |
| Nuveen, LLC | 0.61% | 1,036,987 | -1.9% | 0.01% | $23,083,330 |
| Rockefeller Capital Management L.P. | 0.6% | 1,027,357 | -7.7% | 0.04% | $22,868,967 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
49
Latest
Q1 2026
Rows shown
1-25 of 49
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 164,739,362 | $3,666,700,528 | -$63,003,861 | $22.26 | 339 |
| 2025 Q4 | 166,357,428 | $4,442,292,109 | -$75,199,637 | $26.71 | 333 |
| 2025 Q3 | 167,660,004 | $3,576,680,400 | -$45,558,483 | $21.34 | 329 |
| 2025 Q2 | 169,807,590 | $3,663,065,967 | -$28,402,837 | $21.57 | 308 |
| 2025 Q1 | 171,490,817 | $2,848,881,391 | +$139,123,298 | $16.61 | 315 |
| 2024 Q4 | 162,840,883 | $2,987,247,881 | +$134,856,202 | $18.35 | 292 |
| 2024 Q3 | 155,896,219 | $2,398,194,293 | -$102,074,875 | $15.38 | 257 |
| 2024 Q2 | 161,184,775 | $2,619,212,148 | -$8,478,472 | $16.25 | 265 |
| 2024 Q1 | 161,305,797 | $2,982,051,495 | -$11,656,862 | $18.49 | 266 |
| 2023 Q4 | 159,519,491 | $4,994,576,405 | +$146,161,056 | $31.31 | 272 |
| 2023 Q3 | 156,109,164 | $3,253,545,379 | -$82,496,501 | $20.84 | 246 |
| 2023 Q2 | 159,054,444 | $3,809,481,545 | +$45,597,747 | $23.95 | 232 |
| 2023 Q1 | 158,037,917 | $2,974,292,426 | +$53,351,193 | $18.82 | 231 |
| 2022 Q4 | 155,962,184 | $2,482,889,933 | +$28,684,244 | $15.92 | 221 |
| 2022 Q3 | 152,629,101 | $2,497,282,084 | +$30,373,584 | $16.36 | 213 |
| 2022 Q2 | 150,587,330 | $2,121,823,126 | +$730,128 | $14.09 | 229 |
| 2022 Q1 | 147,043,761 | $3,562,570,671 | -$19,931,550 | $24.22 | 254 |
| 2021 Q4 | 148,180,956 | $3,457,975,885 | +$79,727,176 | $23.34 | 238 |
| 2021 Q3 | 144,785,492 | $2,405,101,667 | -$85,712,883 | $16.61 | 221 |
| 2021 Q2 | 148,041,851 | $3,610,234,111 | +$54,424,511 | $24.39 | 238 |
| 2021 Q1 | 145,061,195 | $3,742,096,150 | -$221,828,762 | $25.80 | 258 |
| 2020 Q4 | 147,844,682 | $7,903,754,877 | -$103,617,443 | $53.46 | 298 |
| 2020 Q3 | 150,041,187 | $6,188,429,775 | -$100,187,840 | $41.25 | 262 |
| 2020 Q2 | 152,670,605 | $7,396,593,388 | -$42,512,386 | $48.47 | 292 |
| 2020 Q1 | 153,864,301 | $6,498,311,210 | +$189,756,698 | $42.25 | 243 |